ANZICS CTG Endorsed Study

BLING III

A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients

Study Description

A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients. This is a prospective, multicentre study with 7000 patients recruited from 100 sites worldwide, open label randomised controlled trial with blinded outcome assessment.

Management Committee

Jeffrey Lipman, Stephen Brett, Menino Cotta, Joshua Davis, Jan De Waele, Joel Dulhunty, Simon Finfer, Parisa Glass, Serena Knowles, Shay McGuinness, John Myburgh, David Paterson, Dorrilyn Rajbhandari (Project Manager), Sandra Peake, Andrew Rhodes, Jason Roberts, Charudatt Shirwadkar, Therese Starr, and Colman Taylor.

Administering Institution

The George Institute for Global Health

Collaborators

University of Queensland

Sample Size

7000 patients

Funding

NHMRC – Project Grant – $3,269,942

Project Status as of June 2018

Recruitment has commenced in Australia at pilot site with all sites expected to start imminently. Collaborations have been established with Imperial College, London, UK and University Ziekenhuis, Gent, Belgium to cover European sites.

Reference

CTG1516-04

Contact

Dorrilyn Rajbhandari (email)
Jeff Lipman (email)
Joel Dulhunty (email)

Clinical Trial Registration No:

NCT03212990 (ClinicalTrials.gov)